Problem

Epia Neuro addresses the gap between intention and movement after stroke. Stroke is a leading cause of long-term disability, and many survivors retain the neural intention to grasp or release objects even though the pathway to the body no longer works. The immediate, high-value use case is restoring enough upper-limb function for people with chronic motor impairment to perform essential daily tasks independently.

The company is positioning this as an assistive-living problem rather than only a rehabilitation problem. Epia estimates that roughly 60,000 U.S. stroke survivors per year could be eligible for its products, representing a potential U.S. market exceeding $5 billion depending on pricing. A lifelong assistive device may also offer a more predictable and reimbursable business model than a therapy product whose clinical and commercial outcomes depend on incremental rehabilitation improvement.

Product / Service

Epia is developing a minimally invasive, long-life “read/write” brain-computer interface that senses neural signals, decodes intent in real time, and delivers stimulation or commands through proprietary algorithms. Its interface is designed to sit without piercing the dura and to be implanted in less than an hour. The system combines the implant and decoder with contextual sensor data and a wearable grip-assist device, translating a patient’s intended movement into practical actions such as grasping and releasing objects.

The platform is designed as a closed-loop system that continuously learns each patient’s neural activity, adapts therapy and stimulation parameters, and supports both post-stroke rehabilitation and long-term assistance after recovery plateaus. Epia also emphasizes a discreet intracranial form factor, non-invasive headset charging, a decades-long intended lifetime, and an upgradeable implant architecture that could reduce the need for repeat invasive surgeries.

Market

Epia competes in medical devices, brain-computer interfaces, neurotechnology, and neuromodulation, with stroke-related motor impairment as its initial clinical wedge. Its longer-term roadmap includes cognitive decline, Parkinson’s disease, epilepsy, and other neurological conditions. Adjacent or emerging BCI competitors identified in the available market coverage include Neuralink, Paradromics, INBRAIN Neuroelectronics, and Neuracle Technology, while Epia’s combination of minimally invasive implantation, closed-loop stimulation, and an everyday assistive device gives it a distinct stroke-focused position.

The company launched publicly in April 2026 after operating quietly for roughly three years, has reported 45 employees, and is backed by venture funding and pharmaceutical investment. It remains pre-commercial: Epia’s own site says the product is investigational and not approved for commercial distribution, while first-in-human system demonstrations were planned with Lenox Hill Hospital later in 2026. No revenue was disclosed in the available sources, so the clearest traction is its assembled team, clinical partnership, platform development, and defined initial market rather than commercial sales.